Advanced Cancer Diagnostics Market: as FDA-approved liquid biopsy and NGS-based companion diagnostics move from advanced-tumour treatment selection into population-scale cancer screening, so companion-diagnostic label expansion and reimbursement decide which platforms scale fastest, and multi-cancer early detection testing opens an addressable population an order of magnitude larger than the companion-diagnostic market alone.

The global advanced cancer diagnostics market size was USD 8.42 Billion in 2025 and is expected to register a revenue CAGR of 14.6% during the forecast period. Market revenue growth is driven by factors such as the clinical scaling of liquid biopsy and NGS-based comprehensive genomic profiling from research into mainstream oncology workflows, the regulatory expansion of companion diagnostic labels across an increasing range of targeted therapies, and the emergence of multi-cancer early detection blood testing as a population screening category. The first driving factor is the transition of liquid biopsy testing from a specialty research tool into routine clinical practice. More than 300 cancer-related genes can now be profiled from a single blood draw using FDA-approved comprehensive genomic profiling platforms, replacing tissue biopsy as the first-line testing approach for a growing share of advanced solid tumour patients. The second driving factor is the regulatory expansion of companion diagnostic labels tied to targeted oncology drug approvals. Comprehensive genomic profiling platforms have accumulated more than 100 FDA-approved companion diagnostic indications in aggregate across breast, lung, prostate, ovarian, and colorectal cancer, with each new targeted therapy approval creating a corresponding diagnostic testing requirement. The third driving factor is the emergence of multi-cancer early detection blood testing as a distinct population-screening category extending beyond the advanced-tumour treatment-selection use case. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single FDA-approved comprehensive genomic profiling platform accumulates additional companion diagnostic indications each time a new targeted oncology therapy reaches approval, which widens its billable use case without requiring a new laboratory relationship or a new regulatory submission process for the underlying test. Once a platform's genomic panel is already FDA-approved and validated, each additional companion diagnostic label added for a newly approved targeted therapy converts existing test volume into a broader set of reimbursable indications without the developer re-validating the panel from scratch, so the platform's indication count compounds in value as the targeted-therapy drug pipeline approving around it grows. As a result, demand and revenue share are concentrating around the comprehensive genomic profiling platforms with the deepest companion diagnostic label portfolios, that hold the broadest set of FDA-approved indications and the most established laboratory infrastructure, and the forecast tilts toward these multi-indication platforms rather than single-indication or lab-developed tests built for one drug at a time. For instance, in January 2025, Foundation Medicine, United States, received FDA approval for its FoundationOne CDx tissue-based platform as the companion diagnostic for a newly approved pediatric low-grade glioma therapy, one of more than 100 companion diagnostic indications the platform now carries across solid tumour types. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is the FDA's approval of blood-based colorectal cancer screening tests for average-risk adults, extending liquid biopsy technology beyond advanced-tumour treatment selection into population-scale preventive screening. This mechanism works because a screening test's addressable population is defined by age-eligibility guidelines covering tens of millions of average-risk adults, while a companion diagnostic's addressable population is limited to the smaller number of patients already diagnosed with a specific advanced cancer, so the two markets differ by orders of magnitude in eligible test volume even when built on the same underlying blood-based sequencing technology. The US Preventive Services Task Force recommends colorectal cancer screening beginning at age 45 for average-risk adults, an eligible population of 60 to 85 million US adults, compared with an estimated 150,000 to 200,000 advanced non-small cell lung cancer cases annually where companion diagnostic liquid biopsy testing has historically generated its revenue. The recent record shows the pace. In April 2025, a leading comprehensive genomic profiling liquid biopsy platform received tumour-agnostic FDA approval enabling a single blood sample to support treatment selection across all solid tumour types at once rather than one cancer type at a time, and in January 2025, Tempus AI announced the national launch of its FDA-approved xT CDx, a 648-gene next-generation sequencing companion diagnostic for solid tumour profiling and therapy selection. The effect on the market is a structural shift in liquid biopsy's addressable population from a narrow treatment-selection cohort to a broad screening population, expanding the ceiling on achievable test volume by an order of magnitude. These are some of the key factors driving revenue growth of the market.

The second driver is the regulatory expansion of companion diagnostic labels tied to targeted oncology drug approvals. This works because CMS's National Coverage Determination for NGS-based comprehensive genomic profiling ties Medicare reimbursement directly to FDA-approved companion diagnostic status, and pharmaceutical companies increasingly co-develop a companion diagnostic alongside each new targeted therapy rather than relying on older single-gene testing, so regulatory approval of the drug and its diagnostic now arrive together. Comprehensive genomic profiling platforms have accumulated more than 100 FDA-approved companion diagnostic indications in aggregate across breast, lung, prostate, ovarian, and colorectal cancer, with each newly approved targeted therapy adding to that count. In January 2025, Foundation Medicine received FDA approval for FoundationOne CDx as the companion diagnostic for a newly approved pediatric low-grade glioma therapy, and in March 2026, Myriad Genetics received FDA approval for its MyChoice CDx test as the companion diagnostic for a PARP inhibitor in advanced ovarian cancer, each adding a new reimbursable indication to an already FDA-approved genomic testing platform. The effect on the market is that comprehensive genomic profiling testing becomes progressively harder to displace once a platform accumulates enough companion diagnostic indications, because oncologists standardize around the platform that covers the broadest set of their patients' potential drug matches. These are some of the key factors driving revenue growth of the market.

“Comprehensive genomic profiling platforms now carry more than 100 FDA-approved companion diagnostic indications in aggregate, with each newly approved targeted therapy adding a new reimbursable use case to an already-validated genomic test.”

The third driver is the emergence of multi-cancer early detection blood testing as a distinct commercial category. This works because a single cell-free DNA methylation assay can simultaneously screen for a signal shared across dozens of cancer types from one blood draw, so the addressable population for one MCED test is the entire screening-eligible adult population rather than patients being tested for one specific cancer at a time. A leading multi-cancer early detection platform is validated to detect a cancer signal shared by more than 50 cancer types from a single blood draw, the large majority of which have no recommended standard screening test today. In June 2025, GRAIL received FDA approval for its Galleri multi-cancer early detection test, the first FDA-approved MCED blood test available for clinical prescription, and other advanced cancer diagnostics platform developers have since disclosed their own MCED development programmes targeting a similar screening population. The effect on the market is the creation of an entirely new liquid biopsy product category whose growth is not bounded by any single cancer type's incidence, unlike companion diagnostic or single-cancer screening tests. These are some of the key factors driving revenue growth of the market.

However, the advanced cancer diagnostics market faces adoption constraints from high test cost relative to tissue biopsy and existing screening alternatives, a narrow current Medicare coverage determination, and the clinical evidence bar required for new screening categories. A comprehensive genomic profiling liquid biopsy test can cost several times more than a standard tissue biopsy collection per published cost estimates, so payer benefit design committees require clinical utility evidence demonstrating that the incremental cost improves treatment selection outcomes before granting broad non-Medicare coverage, and this evidence-generation process extends the lag between FDA approval and full commercial reimbursement. CMS's National Coverage Determination scope compounds this, because current Medicare coverage for NGS-based comprehensive genomic profiling is limited to patients with advanced solid tumours who have progressed after standard therapy or have no alternative therapy, which excludes earlier-line treatment selection and minimal residual disease monitoring applications from the reimbursable use case even as clinical evidence for those applications accumulates. Screening cost-parity with established alternatives is the third constraint, since published analysis has found that blood-based colorectal cancer screening costs would need to decrease substantially to be cost-competitive with colonoscopy for population-level screening programmes evaluated on cost per quality-adjusted life year, so the cost of scaling screening-category liquid biopsy tests is not always recovered at prices payers are willing to reimburse, and multi-cancer early detection platforms without a clear cost-effectiveness case struggle to secure broad coverage. These factors substantially limit advanced cancer diagnostics market growth over the forecast period.

Based on technology, the global advanced cancer diagnostics market is segmented into liquid biopsy tests and services, NGS-based comprehensive genomic profiling, multi-cancer early detection blood tests, and digital pathology and molecular diagnostics. Liquid biopsy tests and services hold the largest revenue share, because blood-based testing avoids the invasiveness and tissue-availability constraints of biopsy collection, which suits the growing share of advanced solid tumour patients for whom a tissue sample is insufficient or unsafe to collect. NGS-based comprehensive genomic profiling and digital pathology remain established for cases where tissue is available and a broader panel is clinically preferred, and they are the standard of care in newly diagnosed disease, but they cannot match liquid biopsy's turnaround-time and access advantage for previously treated or hard-to-biopsy patients. Multi-cancer early detection blood tests are expected to register a rapid revenue growth rate in the global advanced cancer diagnostics market over the forecast period, driven by GRAIL's Galleri FDA approval in June 2025 and the broader industry's investment in methylation-based screening technology extending beyond single-cancer detection.

Based on cancer type, the global advanced cancer diagnostics market is segmented into colorectal cancer, lung cancer, breast cancer, prostate cancer, ovarian cancer, and other cancers. Colorectal cancer holds a significantly large revenue share, because it is the only cancer type served by both an FDA-approved stool-based screening test and an FDA-approved blood-based screening test, which gives it the broadest combined screening test volume of any cancer type in the market. Lung cancer is the second-largest cancer segment for advanced diagnostics revenue, driven by high annual companion diagnostic testing volume tied to multiple targeted therapy treatment-selection pathways. Prostate cancer is expected to register a rapid revenue growth rate in the global advanced cancer diagnostics market over the forecast period, driven by an expanding set of FDA-approved companion diagnostic indications, including Myriad Genetics's March 2026 MyChoice CDx approval, for PARP inhibitor and other targeted therapies in metastatic castration-resistant disease.

Based on end-use, the global advanced cancer diagnostics market is segmented into hospitals and comprehensive cancer centres, reference and clinical diagnostic laboratories, and research institutions and pharma CROs. Reference and clinical diagnostic laboratories hold the largest revenue share, because the CLIA-certified laboratory infrastructure required to run FDA-approved comprehensive genomic profiling and liquid biopsy platforms is concentrated among a small number of specialist commercial laboratories that process the large majority of ordered tests. Hospitals and comprehensive cancer centres are expected to register the fastest revenue growth rate in the global advanced cancer diagnostics market over the forecast period, driven by NCI-designated cancer centres building in-house next-generation sequencing capability to shorten result turnaround time for their own patients.

Based on regional analysis, the advanced cancer diagnostics market in North America accounted for largest revenue share in 2025. The United States leads because the FDA's regulatory framework for companion diagnostic and breakthrough device approval moves faster than most other national regulators, and because the country hosts the highest concentration of NCI-designated comprehensive cancer centres and the largest commercial precision oncology laboratory sector. The CMS National Coverage Determination for NGS-based comprehensive genomic profiling extends the reimbursement framework to the 65 million Medicare beneficiaries, the single largest defined patient population with a direct coverage pathway to advanced genomic testing anywhere in the world. The concentration of FDA approval activity and Medicare and commercial payer coverage decisions in the country also means new liquid biopsy and companion diagnostic platforms are almost always launched in the United States first.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, France, and the United Kingdom represent the three largest national advanced cancer diagnostics markets within Europe. The European Union's In Vitro Diagnostic Regulation sets the companion diagnostic approval pathway across the bloc, while Germany's IQWiG benefit assessment process and France's HAS evaluation of molecular diagnostic innovation each run independent national reimbursement reviews after EU-level regulatory approval, adding a second evaluation layer that FDA-approved platforms do not face in the United States. The result is steady rather than rapid growth, shaped more by sequential national reimbursement review than by underlying clinical demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China, Japan, and South Korea represent the three largest national advanced cancer diagnostics markets within the region. China's rapidly expanding cancer incidence, with the National Cancer Registry documenting over 4.82 million new cancer cases in 2022, creates the patient volume that drives NGS-based comprehensive genomic profiling adoption at Chinese tertiary cancer hospitals, and Exact Sciences's March 2025 minority-stake investment in a Korean liquid biopsy firm to co-develop blood-based colorectal and pancreatic cancer tests signals the strategic priority multinational platform developers place on the region. The region's still-developing reimbursement infrastructure alongside its high and rising cancer incidence leaves more room for volume growth than in the more reimbursement-saturated North American market.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national advanced cancer diagnostics markets within the region, with Brazil's private hospital oncology centres implementing comprehensive genomic profiling for advanced solid tumour treatment selection as the primary Latin American commercial revenue base. Iran-US sanctions and the resulting disruption to shipping through the Strait of Hormuz continue to raise freight and import costs for the sequencing reagents, library-preparation consumables, and temperature-controlled sample-shipping kits that Latin American reference laboratories import from US and European manufacturers, an effect expected to persist through 2026 and to slow comprehensive genomic profiling and liquid biopsy adoption beyond Brazil's and Mexico's main private oncology centres.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Israel, Saudi Arabia, and the United Arab Emirates represent the primary commercial advanced cancer diagnostics markets within the region. Israel is the most established market on the continent, with Sheba Medical Center and Hadassah Medical Center operating precision oncology programmes that integrate comprehensive genomic profiling and liquid biopsy testing into routine clinical workflows, while the Gulf states are still building the local laboratory and reimbursement infrastructure needed to support broad comprehensive genomic profiling adoption.